Immunotherapy in patients with cervical cancer
Immunotherapy, also known as therapy with immune checkpoint inhibitors, has shown good results in the treatment of both solid tumors and hematological malignancies. Patients with diseases that were considered incurable earlier now have an opportunity for long-term disease stabilization and high freq...
Saved in:
| Main Author: | A. G. Kedrova |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2020-11-01
|
| Series: | Опухоли женской репродуктивной системы |
| Subjects: | |
| Online Access: | https://ojrs.abvpress.ru/ojrs/article/view/738 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Adverse drug reaction assessment of pembrolizumab in cervical cancer treatment: a real-world pharmacovigilance study using the FAERS database
by: Huiping Zhang, et al.
Published: (2025-04-01) -
The immunotherapy breakthroughs in cervical cancer: Focus on potential biomarkers and further therapy advances
by: Maja Pezer Naletilić, et al.
Published: (2025-05-01) -
Targeting immune microenvironment in cervical cancer: current research and advances
by: Zhen Zhang, et al.
Published: (2025-08-01) -
The promise of PD1/PDL1 targeted immunotherapy in locally advanced cervical cancer: a game-changer for patients outcome?
by: Fadila Kouhen, et al.
Published: (2025-05-01) -
Therapeutic Indications of Pembrolizumab in Eight Common Cancers: Current Evidence and Future Directions
by: Raghed Mansour, et al.
Published: (2025-07-01)